Serum Lactate Dehydrogenase Is a Sensitive Predictor of Systemic Complications of Acute Pancreatitis

Background Acute pancreatitis (AP) is a common and potentially life-threatening inflammatory disease that can cause various complications, including systemic inflammatory response syndrome (SIRS), pleural effusion, ascitic fluid, myocardial infarction, and acute kidney injury (AKI). However, there is still a lack of rapid and effective indicators to assess the disease. The aim of this study was to investigate the associations of high serum lactate dehydrogenase (LDH) levels with AP severity and systemic complications. Methods AP patients treated from July 2014 to December 2020 were retrospectively enrolled. They were divided into elevated (n = 93) and normal (n = 143) LDH groups. Their demographic data, clinical data, hospital duration, and hospital expenses were analyzed. Linear and binary logistic regression analyses were used to determine whether elevated LDH is a risk factor for AP severity and complications after adjusting for confounders. Results There were significant differences in AP severity scores (Ranson, MODS, BISAP, APACHE II, and CTSI), hospital duration, hospital expenses, and the incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI) between the elevated and normal LDH groups. After adjusting for confounders, elevated LDH was associated with AP severity scores and hospital duration and expenses (based on linear regression analyses) and was a risk factor for the occurrence of AP complications and interventions, that is, diuretic and vasoactive agent use (based on binary logistic regression analyses). Conclusions Elevated LDH is associated with high AP severity scores and high incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI).


Introduction
Acute pancreatitis (AP) is the most common pancreatic disease in emergency departments [1]. A prospective study reported that the mortality rate of AP is 9.1% [2]. AP can rapidly cause various local and systemic complications, such as acute kidney injury (AKI), respiratory failure, and heart failure [3,4], which can lead to death [5][6][7]. Complications represent the most important factor leading to a poor prognosis in patients with AP. Unfortunately, there is a lack of effective, rapid, and simple markers to assess AP complications.
Lactate dehydrogenase (LDH) has been widely used to evaluate AP severity [8]. In addition, several studies have confirmed that serum LDH is increased in heart and chest diseases (e.g., myocardial infarction [9,10], acute heart failure [11], and pleural effusion [12]). Moreover, a narrative review indicated that elevated LDH in patients with rhabdomyolysis can predict the occurrence of AKI [13]. However, whether LDH is an indicator of complications in patients with AP remains unclear.
Therefore, this study aims to explore the associations of serum LDH with AP severity and systemic complications.

Materials and Methods
2.1. Participants. Retrospective data on AP patients treated at the First Affiliated Hospital of Guangdong Pharmaceutical University from July 2014 to December 2020 were included. Exclusion criteria were pregnancy, prior organ transplantation, chronic pancreatitis, and incomplete electronic medical records.  [4], the diagnosis of AP was based on at least two of the following three features: characteristic abdominal pain, serum amylase or lipase over three times the upper limit of normal, and characteristic findings on abdominal imaging. Elevated serum LDH was defined as >290 U/L [14,15]. AP severity was assessed according to the Ranson score [16], Multiple Organ Dysfunction Syndrome (MODS) score [17], Bedside Index for Severity in Acute Pancreatitis (BISAP) score [18], Acute Physiology Assessment and Chronic Health Evaluation (APACHE) II score [19], modified Computed Tomography Severity Index (CTSI) [20], and Charlson Comorbidity Index (CCI) [21]. Hypocalcemia was defined as serum calcium <2.12 mmol/L [22]. AKI [23], acute respiratory failure (ARF) [24], and acute heart failure [25] were defined as described in the cited guidelines.

Statistical Analysis.
All data analyses were performed in the SPSS software v22.0 (IBM Corporation, Armonk, NY, USA). Data normality was assessed by the Shapiro-Wilk test. Continuous variables with normal and non-normal distribution were analyzed by t-tests and Mann-Whitney U tests, respectively. Categorical variables were analyzed by chi square tests. Continuous variables are expressed as mean ± standard deviation or median (interquartile range [IQR]), and categorical variables are expressed as frequency (percentage).
Backward stepwise linear regression analyses were used to determine whether elevated LDH (>290 U/L) was a risk factor for AP severity score, hospital duration, and hospital expenses. Backward stepwise binary logistic regression analyses were used to determine whether elevated LDH (>290 U/ L) was a risk factor for AP complications and interventions. The analyses were adjusted for potential confounders (gender, age, hypocalcemia, and serum lipase, amylase, glucose, ALT, and AST). Results were considered significant if P < 0:05.

Patient Characteristics.
Based on the inclusion and exclusion criteria, 236 patients with AP were enrolled in this 2 Gastroenterology Research and Practice study. They were divided into elevated (n = 93) and normal (n = 143) LDH groups according to serum LDH levels. The demographic and clinical data of the enrolled patients are presented in Table 1.

Discussion
In this study, the AP patients with high LDH levels had severer disease (higher Ranson, MODS, BISAP, APACHE II, and CTSI scores), higher risks of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI), and worse prognosis (higher incidence of diuretic agent use, longer hospital duration, and higher hospital expenses) than those with normal LDH levels. Therefore, assessing LDH at the early stage is likely to be useful for predicting the incidence of complications and then improving prognosis 3 Gastroenterology Research and Practice by intervening early. To our knowledge, this is the first study to systematically assess the relationship between high LDH levels and multiple complications in AP patients.
Previous studies revealed the close association between LDH and AP severity. First, LDH is one of the 11 metrics in the Ranson score, which is an important milestone regarding AP severity scoring systems [16]. Second, Tian et al. found that the LDH level was approximately two times higher in severe AP patients than that in mild AP patients, and they reported that LDH is a reliable predictor of severe AP (82.7% sensitivity and 96% specificity) [8]. Additionally, a decision tree model [26], which used LDH to predict severe AP, revealed that 63.6% of patients were identified as having severe AP at LDH > 536 U/L, and the overall accuracy of the model was 88.5%. Thus, the decision tree model showed that LDH is likely to be useful for predicting the occurrence of severe AP.
Several recent clinical studies have also indicated that serum LDH is a major risk factor for developing complications in multiple diseases. For instance, LDH levels were significantly elevated in patients with rhabdomyolysis-induced AKI [13]. Second, a study of sickle cell anemia showed a significant positive association between LDH and sickle cell anemia-related leg ulcer recurrence [27]. Third, in cardiothoracic surgery patients, the odds of postoperative cardiopulmonary complications increased by nearly 2-fold for each 100 U/L increase in preoperative LDH [28]. Fourth, a study revealed that LDH was considerably higher in patients with malignant ascites than in patients with benign ascites, and it was a risk factor for malignant ascites [29]. Fifth, a retrospective study of 988 patients with metastatic cancer reported that higher LDH was associated with an increased risk of pleural effusion recurrence [30]. Finally, a recent study reported that patients with higher LDH had a higher risk of stage 3 AKI than patients with lower LDH [31]. In line with these previous studies, we found that the incidences of pleural effusion, ascitic fluid, and AKI were 1.906, 2.594, and 4.277 higher in AP patients with elevated LDH than in those with normal LDH.
The relationship between elevated LDH and AP complications can be partly explained by the following factors. First, several AP complications, such as pleural effusion [32], ascitic fluid [33], and AKI [34], are accompanied by inflammatory reactions, which lead to cell damage and necrosis, cause LDH release into the serum, and ultimately raise the level of LDH. Second, research indicates that the primary source of elevated LDH in severe AP is likely to be the kidneys [35] rather than the pancreas [36], indicating that patients with elevated LDH may have renal complications, such as AKI.
In addition, we found that diuretic agent use was higher in the elevated LDH group than that in the normal group, which may be due to there being a higher incidence of AKI in the elevated LDH group. We also found that AP patients with higher LDH have longer hospital duration and higher hospital expenses, which may be related to severer AP and more complications, thus requiring additional medications and monitoring. Consequently, clinicians should carefully monitor serum LDH in AP patients and provide timely preventative interventions if the LDH level is high, in order to improve prognosis.
Our research has several inevitable limitations. First, the lack of blood samples available in this retrospective study limited research on the mechanisms. Second, although we adjusted for many potential confounders in our analyses,

Conclusions
Elevated LDH is associated with both high AP severity scores and high incidences of multiple complications (SIRS, pleural effusion, ascitic fluid, and AKI). Therefore, the levels of LDH in AP patients should be closely monitored after hospital admission so that the complications can be recognized early and treated promptly.

Data Availability
Readers can obtain the datasets of the current study on reasonable request by contacting the author Dong-Ni Huang via email (hdongni@qq.com).

Conflicts of Interest
The authors declare that they have no conflicts of interest.